La Louviere

• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 4 2023-06-02 Metastatic Colorectal Cancer (mCRC)
• First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients Ended
  2022-501183-17-00 7 2023-02-23 Non-Small Cell Lung Cancer
• Study to compare overall survival (OS) between subjects who receive SBP-101 and those who do not receive SBP-101 (i.e., placebo) in combinat … Ended
  2024-514714-12-00 10 2022-11-11 Metastatic Pancreatic Ductal Adenocarcinoma
• Cohort study of human mpox virus disease Ended
  2022-501132-42-00 6 2022-08-02 Monkeypox virus disease
• A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu … Ended
  2023-507189-17-00 4 2022-01-09 Muscle-Invasive Urothelial Carcinoma of the Bladder
• A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi … Ended
  2024-511972-33-00 5 2019-08-05 Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-
• A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended
  2023-506543-41-00 5 2018-07-25 Multiple sclerosis (MS)
• Predictive factors and magnitude of response to omalizumab and mepolizumab in allergic and eosinophilic severe asthma: PREDICTUMAB, an open- … Ended
  2024-516783-29-00 6 2018-04-16 Severe allergic and eosinophilic asthma
• A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP ( … Ended
  2024-516904-40-00 5 2018-03-27 Previously Untreated Diffuse large B-cell lymphoma (DLBCL)
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• Phase II study evaluating peptide-based immunotherapies as monotherapy for 3 weeks prior to standard treatment for head and neck cancer. Ended
  2024-513447-82-00 4 squamous cell carcinoma of the head and neck

Showing 97–108 of 108 trials